PL3752251T3 - Inhibitory arginazy i sposoby ich stosowania - Google Patents

Inhibitory arginazy i sposoby ich stosowania

Info

Publication number
PL3752251T3
PL3752251T3 PL19710796.4T PL19710796T PL3752251T3 PL 3752251 T3 PL3752251 T3 PL 3752251T3 PL 19710796 T PL19710796 T PL 19710796T PL 3752251 T3 PL3752251 T3 PL 3752251T3
Authority
PL
Poland
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
PL19710796.4T
Other languages
English (en)
Other versions
PL3752251T4 (pl
Inventor
Scott Nathan MLYNARSKI
Tyler GREBE
Sameer KAWATKAR
Maurice Raymond Verschoyle Finlay
Iain Simpson
Jianyan Wang
Steve Cook
Dedong Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3752251T3 publication Critical patent/PL3752251T3/pl
Publication of PL3752251T4 publication Critical patent/PL3752251T4/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19710796.4T 2018-02-17 2019-02-15 Inhibitory arginazy i sposoby ich stosowania PL3752251T4 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11
PCT/IB2019/051236 WO2019159120A1 (en) 2018-02-17 2019-02-15 Arginase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
PL3752251T3 true PL3752251T3 (pl) 2026-02-16
PL3752251T4 PL3752251T4 (pl) 2026-02-16

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19710796.4T PL3752251T4 (pl) 2018-02-17 2019-02-15 Inhibitory arginazy i sposoby ich stosowania

Country Status (34)

Country Link
US (4) US11420984B2 (pl)
EP (2) EP4678238A2 (pl)
JP (2) JP7317841B2 (pl)
KR (1) KR102657919B1 (pl)
CN (3) CN117186134A (pl)
AU (2) AU2019221896B2 (pl)
BR (1) BR112020015973A2 (pl)
CA (1) CA3091365A1 (pl)
CL (1) CL2020002096A1 (pl)
CR (1) CR20200418A (pl)
DK (1) DK3752251T3 (pl)
DO (1) DOP2020000145A (pl)
EC (1) ECSP20058183A (pl)
ES (1) ES3058584T3 (pl)
FI (1) FI3752251T3 (pl)
HR (1) HRP20251592T1 (pl)
IL (1) IL276711B2 (pl)
JO (1) JOP20200197A1 (pl)
LT (1) LT3752251T (pl)
MA (1) MA51837B1 (pl)
MX (1) MX2020008570A (pl)
NI (1) NI202000055A (pl)
PE (1) PE20210176A1 (pl)
PL (1) PL3752251T4 (pl)
PT (1) PT3752251T (pl)
RS (1) RS67559B1 (pl)
SG (1) SG11202007739XA (pl)
SI (1) SI3752251T1 (pl)
SM (1) SMT202500499T1 (pl)
TW (1) TWI803574B (pl)
UA (1) UA129083C2 (pl)
UY (1) UY38096A (pl)
WO (1) WO2019159120A1 (pl)
ZA (2) ZA202305542B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
KR102668252B1 (ko) 2018-08-22 2024-05-21 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12021551902A1 (en) * 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN114599372A (zh) * 2019-11-04 2022-06-07 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CN119213001A (zh) * 2022-06-08 2024-12-27 株式会社大熊制药 精氨酸酶抑制剂和包含其的药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027034B1 (pt) * 2010-04-22 2020-10-13 Mars, Incorporated compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CN103402549A (zh) 2010-12-31 2013-11-20 考瑞多制药公司 精氨酸酶抑制剂及其使用方法
IN2014DN09678A (pl) 2012-04-18 2015-07-31 Mars Inc
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
EP3842442B1 (en) 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
US11655260B2 (en) 2017-12-22 2023-05-23 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
PH12021551902A1 (en) * 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
HRP20251592T1 (hr) 2026-02-13
ES3058584T3 (en) 2026-03-11
ZA202407941B (en) 2025-06-25
WO2019159120A1 (en) 2019-08-22
IL276711A (en) 2020-09-30
UY38096A (es) 2019-07-31
PL3752251T4 (pl) 2026-02-16
ECSP20058183A (es) 2020-10-30
EP4678238A2 (en) 2026-01-14
DK3752251T3 (da) 2025-12-15
IL276711B2 (en) 2024-06-01
CR20200418A (es) 2020-10-27
UA129083C2 (uk) 2025-01-08
CN111712302A (zh) 2020-09-25
US12195485B2 (en) 2025-01-14
KR20200122341A (ko) 2020-10-27
US20230365599A1 (en) 2023-11-16
NZ767738A (en) 2023-12-22
AU2019221896B2 (en) 2022-03-24
MA51837B1 (fr) 2025-12-31
SMT202500499T1 (it) 2026-01-12
CA3091365A1 (en) 2019-08-22
AU2022203938A1 (en) 2022-06-23
JOP20200197A1 (ar) 2020-08-16
AU2022203938B2 (en) 2024-02-01
US11420984B2 (en) 2022-08-23
RS67559B1 (sr) 2026-01-30
IL276711B1 (en) 2024-02-01
US20210002305A1 (en) 2021-01-07
NI202000055A (es) 2021-06-22
FI3752251T3 (fi) 2025-12-12
TW201945004A (zh) 2019-12-01
SI3752251T1 (sl) 2026-02-27
CN111712302B (zh) 2023-09-19
CL2020002096A1 (es) 2020-12-18
ZA202305542B (en) 2025-03-26
LT3752251T (lt) 2026-01-12
AU2019221896A1 (en) 2020-10-01
JP2023145557A (ja) 2023-10-11
EP3752251A1 (en) 2020-12-23
PE20210176A1 (es) 2021-01-29
TWI803574B (zh) 2023-06-01
BR112020015973A2 (pt) 2020-12-15
CN117186134A (zh) 2023-12-08
MA51837A (fr) 2021-06-16
EP3752251B1 (en) 2025-09-10
KR102657919B1 (ko) 2024-04-15
US20230122859A1 (en) 2023-04-20
US11912727B2 (en) 2024-02-27
PT3752251T (pt) 2026-01-13
JP2021513964A (ja) 2021-06-03
SG11202007739XA (en) 2020-09-29
MX2020008570A (es) 2020-09-21
DOP2020000145A (es) 2020-09-15
JP7699171B2 (ja) 2025-06-26
CN117180290A (zh) 2023-12-08
US20250313578A1 (en) 2025-10-09
JP7317841B2 (ja) 2023-07-31

Similar Documents

Publication Publication Date Title
IL287940A (en) Fgfr inhibitors and methods of use thereof
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
PL3752251T4 (pl) Inhibitory arginazy i sposoby ich stosowania
IL284661A (en) Pcsk9 inhibitors and methods of use thereof
IL283592A (en) Inhibitors of apol1 and methods of using same
IL287787A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287795A (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL288996A (en) Aminopyrimidine amide autophagy inhibitors and methods of use thereof
PL3788047T3 (pl) Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
DK3559009T3 (da) Sammensætninger og metoder til inhibition af arginaseaktivitet
EP3761992A4 (en) ARGINASE INHIBITORS
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
DK3840837T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
IL292860A (en) Allosteric egfr inhibitors and methods of use thereof
EP4017857A4 (en) METTL 16 INHIBITORS AND THEIR USES
ZA202105833B (en) Arginase inhibitors and methods of use thereof
IL268771A (en) Peptide kinase inhibitors and methods of use thereof
DK3781558T3 (da) Hæmmere af blodpladefunktion og fremgangsmåder til anvendelse heraf
IL309389A (en) E3 ligase inhibitors and methods of use thereof
TH2001004951A (th) สารยับยั้งอาร์จิเนส